Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)
Primary Purpose
Diabetes Mellitus, Non-Insulin-Dependent
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
sitagliptin phosphate
Comparator: metformin
Comparator: metformin
Comparator: Antidiabetic Standard of Care
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Non-Insulin-Dependent
Eligibility Criteria
Inclusion Criteria:
- Patient Has Type 2 Diabetes Mellitus
- Patient Is 30-78 Years Of Age On The Day Of Signing Informed Consent
- Patient Is Currently On Metformin Therapy (1500 Mg/Day)
- Patient Is A Male Or A Female Who Is Unlikely To Conceive, As Indicated By At Least One Yes Answer To The Following Questions: A) Patient Is A Male. B) Patient Is A Surgically Sterilized Female. C) Patient Is A Postmenopausal Female 45 Years Of Age With >2 Years Since Last Menses. D) Patient Is A Non-Sterilized Premenopausal Female And Agrees To Use An Adequate Method Of Contraception To Prevent Pregnancy Throughout The Study Starting With Visit 1 And For 14 Days After The Last Dose Of Study Medication
- Patient Understands The Study Procedures, The Alternative Treatments Available, The Risks Involved In The Study And Voluntarily Agrees To Participate By Giving Written Informed Consent
- Patient Has An A1c of 6.5 % - 11.0%
Exclusion Criteria:
- Patient Has A History Of Type 1 Diabetes Mellitus Or History Of Ketoacidosis
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
1
2
3
Arm Description
sitagliptin + metformin
metformin + any other oral antidiabetic drug
metformin
Outcomes
Primary Outcome Measures
Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24
Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00875394
Brief Title
Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)
Official Title
A Multicenter, Randomized, Open-label Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With T2 DM With Inadequate Glycemic Control on Metformin
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
February 1, 2007 (Actual)
Primary Completion Date
June 27, 2008 (Actual)
Study Completion Date
June 27, 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
After 24 weeks of treatment, to assess the A1C-lowering efficacy of sitagliptin 100 mg once daily added to the regimen of patients with inadequate glycemic control on metformin monotherapy
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Non-Insulin-Dependent
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
68 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
sitagliptin + metformin
Arm Title
2
Arm Type
Active Comparator
Arm Description
metformin + any other oral antidiabetic drug
Arm Title
3
Arm Type
Active Comparator
Arm Description
metformin
Intervention Type
Drug
Intervention Name(s)
sitagliptin phosphate
Other Intervention Name(s)
sitagliptin
Intervention Description
sitagliptin 100 mg Once a day (QD) for 24 weeks
Intervention Type
Drug
Intervention Name(s)
Comparator: metformin
Other Intervention Name(s)
metformin
Intervention Description
metformin 850 mg Twice a day (BID) for 24 weeks
Intervention Type
Drug
Intervention Name(s)
Comparator: metformin
Other Intervention Name(s)
metformin
Intervention Description
metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
Intervention Type
Drug
Intervention Name(s)
Comparator: Antidiabetic Standard of Care
Intervention Description
Patient can take any oral antidiabetic drug (other than metformin)
Primary Outcome Measure Information:
Title
Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24
Description
Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values.
Time Frame
Baseline and 24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
78 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient Has Type 2 Diabetes Mellitus
Patient Is 30-78 Years Of Age On The Day Of Signing Informed Consent
Patient Is Currently On Metformin Therapy (1500 Mg/Day)
Patient Is A Male Or A Female Who Is Unlikely To Conceive, As Indicated By At Least One Yes Answer To The Following Questions: A) Patient Is A Male. B) Patient Is A Surgically Sterilized Female. C) Patient Is A Postmenopausal Female 45 Years Of Age With >2 Years Since Last Menses. D) Patient Is A Non-Sterilized Premenopausal Female And Agrees To Use An Adequate Method Of Contraception To Prevent Pregnancy Throughout The Study Starting With Visit 1 And For 14 Days After The Last Dose Of Study Medication
Patient Understands The Study Procedures, The Alternative Treatments Available, The Risks Involved In The Study And Voluntarily Agrees To Participate By Giving Written Informed Consent
Patient Has An A1c of 6.5 % - 11.0%
Exclusion Criteria:
Patient Has A History Of Type 1 Diabetes Mellitus Or History Of Ketoacidosis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
Learn more about this trial
Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)
We'll reach out to this number within 24 hrs